Product information and disease descriptionProduct description
Phase of product development
9 evidence topics · 13 sources
Regulatory status: Submission planned; NDA planned after VANQUISH phase 3 data expected in the second half of 2027
Launch: Anticipated about two and a half years after October 2026
Subcutaneous formulation: FDA Type C meeting and end-of-phase 2 meeting before phase 3
Subcutaneous formulation: VANQUISH phase 3 program initiation and enrollment
Subcutaneous formulation: VANQUISH extension studies and timing of a supplemental application
Oral formulation: end-of-phase 2 meeting with the FDA
Oral formulation: SUNRISE phase 3 program initiation and expected data timing
Development history: first clinical studies of each formulation
Expedited program designations
No evidence found.
Patent estate for the GLP-1 agonist program
| Subject matter | Pending applications | Issued patents | Nominal patent term |
|---|---|---|---|
| GLP-1 agonists, as of December 31, 2025 | “113” | “13” | “2042-2045” |